Hologic Inc (NASDAQ: HOLX) has reported E.P.S. of $0.72 for its second fiscal quarter (ending March 31) versus $0.88 for the same period a year ago — a decline of -18%. Relative to the consensus estimate of $1.08, this was a shortfall of $-0.36. E.P.S. were $1.97 for the latest four quarters through March 31 versus $3.02 for the same period a year ago — a decline of -35%.
Recent Price Action
Hologic Inc (NASDAQ: HOLX) stock declined slightly by -0.5% on 5/2/24. The stock closed at $75.91. This decline was accompanied by normal trading volume. The stock has performed in line with the market over the last nine months and has declined -1.0% during the last week.
Current PriceTarget Research Rating
HOLX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Hologic has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Hologic has a poor Appreciation Score of 28 but a neutral Power Rating of 56, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment